top of page

Inflection Biosciences Shortlisted for The Pharma Industry Awards 2014

Dublin, Ireland, October 1, 2014

Inflection Biosciences Ltd, a private company developing highly innovative treatments for cancer, today announced that it has been shortlisted for the inaugural Pharma Industry Awards 2014 in the ‘Start-up Company of the Year’ category.

The Pharma Industry Awards recognise and celebrate the most original and innovative individuals and companies that demonstrate excellence in the Irish Pharma sector. This ‘Start-up Company of the Year’ award is open to any company established within the last 3 years working in the biotech, biopharma or pharmaceutical sector in Ireland. The winners will be announced at The Pharma Industry Awards 2014 on Wednesday, October 29th at the Ballsbridge Hotel, Dublin 4.

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises a unique dual mechanism pan-PIM/PI3 kinase inhibitor program and a pan-PIM kinase inhibitor program, both in preclinical development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. For more information please visit the Company’s website at


bottom of page